Abstract: Disclosed is a soluble, biocompatible, pharmacological agent for inhibiting thrombin generation and thrombus formation, and methods for producing the same. The pharmacological agent or conjugate includes a soluble, biocompatible carrier and a thrombogenesis inhibitor immobilized thereto via the carrier which binds the inhibitor. The thrombogenesis inhibitor is hirudin, or an active analog or active fragment thereof. The thrombogenesis inhibitor may be bound to the carrier via a bifunctional cross-linking reagent.

Abstract: Disclosed is a method of treating cancer using nutritional support therapy by administration of a structured lipid containing both .omega.3 fatty acids and medium-chain fatty acids. The therapy may be used as total parenteral nutrition or as a nutritional supplement. The addition of tumor necrosis factor may also be beneficial.

Abstract: Disclosed is a biocompatible, thromboresistant substance useful for implantable and extracorporeal devices in contact with the vascular system, and methods for producing the same. The biocompatible, thromboresistant substance comprises a synthetic, biocompatible material, at least one biocompatible base coat layer adhered to at least one surface of the material, and a thrombogenesis inhibitor immobilized on the base coat layer via a component capable of binding the inhibitor. The thrombogenesis inhibitor is streptokinase, urokinase, tissue plasminogen activator, ATPase, 5'-nucleotidase, and active fragments and active analogs thereof.

Abstract: A new marker for colorectal carcinoma has been discovered which is a goycoprotein having a molecular weight of approximately 160,000 daltons. Assay methods which can identify this marker are useful in detecting, diagnosing, and monitoring colorectal carcinoma, and in particular, carcinoma of the undifferentiated variety which heretofor were not readily detectible. For example, an assay which utilizes an antibody reacting to this glycoprotein marker is useful in a screening method for the detection and monitoring of colorectal carcinoma cells. Such an antibody can be included as part of a kit for screening a patient for colorectal carcinoma.

Abstract: Disclosed are methods of rapidly and accurately detecting a compound-of interest, such as a toxic drug, in a body fluid. A liquid sample containing various native constituents and an anticipated exogenous chemical compound is obtained from the body. The sample is then subjected to analysis by ion mobility spectrometry to determine the presence of the exogenous chemical compound or related metabolite therein. The method may further include the step of separating the compound-of-interest from said native constituents in said fluid sample prior to analysis.

Abstract: The present invention features a transesterification product of a mixture of fatty acids and triglycerides which include dairy fat as a primary component. This composition shows unexpected benefits in nutritional applications either as a food or as an enteral or parenteral supplement. The method of nutritional support using this composition is also disclosed.

Abstract: A new marker for colorectal carcinoma has been discovered which is a glycoprotein having a molecular weight of approximately 160,000 daltons. Assay methods which can identify this marker are useful indetecting, diagnosing, and monitoring colorectal carcinoma, and in particular, carcinoma of the undifferentiated variety which heretofor were not readily detectible. For example, an assay which utilizes an antibody reacting to this glycoprotein marker is useful in a screening method for the detection and monitoring of colorectal carcinoma cells. Such an antibody can be included as part of a kit for screening a patient for colorectal carcinoma.

Abstract: Disclosed is a glycoprotein, carcinoma orosomucoid-related antigen, (CORA), which has a binding affinity for carcinoembryonic antigen (CEA). This glycoprotein is a marker for carcinoma, and can be characteried by having a molecular weight of about 46,000-50,000 daltons, an isoelectric point of about 3.0-3.5, a carbohydrate content of about 25-35% by weight, reactivity with antisera raised thereto, and substantially no reactivity with antisera raised to nonspecific cross-reacting antigen (NCA) or to CEA. Also disclosed are a hybridoma which produces a monoclonal antibody to CORA, the monoclonal antibody to CORA, and a device, kit, and method for detecting and monitoring carcinoma.

Abstract: A method of treating cancer cachexia syndrome has been discovered. Total parenteral nutrition using structured lipids in place of long chain fatty acids as the primary lipid source provides improvements in nitrogens balance, plasma serum albumin levels, and glucose clearance rate.

Abstract: A monoclonal antibody raised to colorectal carcinoma, and a hybridoma which elicits the antibody, have been produced. This antibody, ND4 has been discovered to react with a new tumor marker, a glycoprotein of approximately 160 kD found on the surface of undifferentiated colorectal carcinoma cells; it does not cross-react with other known tumor markers. It is useful for detecting and monitoring colorectal carcinoma.

Abstract: Vascular diseases including asymptomatic atherosclerosis can be diagnosed by administering a conjugate diagnostic reagent to a patient and then detecting the location and concentration of the conjugate reagent within the patient's vascular system. The conjugate reagents have a target-seeking, biologically active molecule as one component and a labeling means capable of extracorporeal detection as the other component. The biologically active molecules (BAMs) are chosen to have affinity for structural elements of the arterial wall which are either not present in the normal wall but are found in atherosclerotic or arteritic lesions, or which are not available to the blood-borne reagent within normal arterial walls, but are exposed to the reagent in atherosclerotic or arteriotic lesions.

Abstract: A new dietary supplement has been developed which yields the benefits of both .omega.3 oils and medium chain triglycerides for lipid nutrition. A structured lipid containing .omega.3 fatty acids and medium chain fatty acids is also disclosed.

Abstract: Disclosed is a method of minimizing infection and minimizing the risks of infection in at risk animals and patients. A dietary supplement to accomplish this objective is also disclosed. The method includes the step of administering a diet rich in .omega.3 fatty acids, for example by adding a substantial proportion of fish oils to the diet. The dietary supplement is particularly well suited to patients receiving total parenteral nutrition. A parenteral diet or diet supplement containing a mixture of oils, one rich in .omega.3 fatty acids and the other rich in .omega.6 fatty acids is disclosed.

Abstract: A method of treating, and a diet composition for treating patients needing a controlled diet, wherein C.sub.12 fatty acids are the primary fatty acid source. Preferably lauric fats constitute 33-80% of the diet, while LCT's constitute no more than 20%. The lauric fats may be derived from a natural or fractionated kernel oil, selected from a group consisting of babassu oil, coconut oil, cohune oil, palm kernel oil, and tucum oil. A lipid emulsion with diverse additives is described.

Abstract: The disclosure concerns a synthetic conjugate, methods of constructing this conjugate, and methods of using a conjugate of this type to replace naturally occurring proteins or inhibiting the reaction between a naturally occurring protein and a defined site of biological activity in a vertebrate.